DBI-001 antifungal soil probiotic for treatment and prevention of TR4 in banana crops
DBI-001 is a dried, granulated live bacterial soil probiotic that inhibits Fusarium pathogens including Tropical Race 4 (TR4), the fungus threatening global banana production. Derived from a naturally occurring, safe skin bacterium, it produces multiple antifungal compounds effective against multidrug-resistant fungi in humans, amphibians, and plants. The product is shelf-stable for at least six months at room temperature and is positioned for agricultural deployment.
Overview
DBI-001 is a live biotherapeutic soil probiotic developed to treat and prevent Tropical Race 4 (TR4) and related Fusarium infections in banana cultivation. TR4 is a devastating soil-borne fungal pathogen that threatens global banana production, and current management options are limited. DBI-001 leverages a naturally occurring bacterial strain isolated from animal and human skin that is safe, environmentally common, and capable of producing multiple antifungal compounds. The product is formulated as a dried, granulated powder for straightforward soil application at the root zone of banana plants, where it can suppress Fusarium colonization and reduce disease incidence.
Beyond agriculture, DBI-001 has demonstrated broad antifungal activity, including inhibition of multidrug-resistant fungal pathogens in humans and protection of wild amphibian populations from lethal chytrid infections. This cross-domain efficacy highlights the robustness of its antifungal mechanism and supports its potential as a versatile biocontrol agent.
Technical specifications
- Active ingredient: Live bacterial strain derived from skin microbiome, selected for broad-spectrum antifungal compound production
- Target pathogens: TR4 (Fusarium oxysporum cubense Tropical Race 4) and related Fusarium species, including plant and human Fusarium isolates
- Formulation: Dried, granulated live bacterial product designed for soil application
- Manufacturing process: Animal-component-free fermentation followed by lyophilization and spray drying
- Shelf life: At least six months at room temperature
- Mode of action: Production of multiple antifungal compounds that inhibit Fusarium growth and activity
- Companion diagnostic: Molecular diagnostic previously validated in human samples, adaptable for monitoring DBI-001 abundance and activity in soil and plant tissue
Technology readiness level
DBI-001 is currently at an early-to-mid stage of development for the agricultural application. DermBiont has completed in vitro screening against three plant Fusarium pathogens and one human Fusarium pathogen, with successful inhibition demonstrated across all four isolates. Manufacturing methods for a shelf-stable dried formulation have already been established. Next steps include expanded in vitro screening against a broader TR4 strain library to determine minimum inhibitory abundance and optimal environmental conditions, followed by greenhouse and field trials in collaboration with agricultural partners. The molecular diagnostic tool is ready for validation in environmental samples to support deployment monitoring.
About DermBiont
DermBiont is a biotechnology company focused on developing precision dermatology treatments that address the root causes of skin diseases. The company utilizes a dual-platform approach to therapeutic development: a computational biology platform that analyzes skin microbiome data to create biotherapeutics, and a discovery platform dedicated to targeted small molecule therapeutics. By focusing on these well-defined mechanisms of action, the company aims to move beyond merely treating symptoms and instead provide effective cures for various dermatological conditions. Their lead candidate, SM-030, is a first-in-class topical PKC-beta inhibitor currently being advanced for the treatment of melasma and other hyperpigmentation disorders.
This research is significant for patients suffering from persistent skin conditions, as the company works to fill unmet needs through clinical programs that prioritize efficiency in both timelines and budget. DermBiont’s broader pipeline includes candidates for indications such as seborrheic keratosis, atopic dermatitis, and fungal infections like tinea pedis and onychomycosis. By combining expertise in small molecule development with innovative microbiome insights, DermBiont aims to become a leader in the commercialization of targeted topical therapeutics that improve skin health and quality of life for millions.
delivered to your inbox.